State Board of Administration of Florida Retirement System boosted its position in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 12.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 26,844 shares of the company’s stock after buying an additional 2,963 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Pacira Biosciences were worth $1,022,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PCRX. Rice Hall James & Associates LLC boosted its position in Pacira Biosciences by 2.7% in the first quarter. Rice Hall James & Associates LLC now owns 464,040 shares of the company’s stock valued at $17,661,000 after buying an additional 12,213 shares during the last quarter. Baillie Gifford & Co. boosted its position in Pacira Biosciences by 6.1% in the first quarter. Baillie Gifford & Co. now owns 990,908 shares of the company’s stock valued at $37,715,000 after buying an additional 57,367 shares during the last quarter. Quantamental Technologies LLC purchased a new stake in Pacira Biosciences in the first quarter valued at approximately $162,000. Bank of Montreal Can boosted its position in Pacira Biosciences by 10.0% in the first quarter. Bank of Montreal Can now owns 42,750 shares of the company’s stock valued at $1,627,000 after buying an additional 3,880 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its position in Pacira Biosciences by 96.0% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 24,620 shares of the company’s stock valued at $937,000 after buying an additional 12,060 shares during the last quarter. 99.13% of the stock is owned by institutional investors.

Pacira Biosciences stock opened at $43.51 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 7.83 and a current ratio of 8.62. Pacira Biosciences Inc has a 12 month low of $30.00 and a 12 month high of $55.00. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 88.92, a P/E/G ratio of 2.46 and a beta of 1.47.

Pacira Biosciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.22 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.20. Pacira Biosciences had a return on equity of 6.78% and a net margin of 2.10%. The business had revenue of $91.31 million for the quarter, compared to analyst estimates of $92.13 million. During the same quarter in the prior year, the firm posted $0.02 EPS. The business’s quarterly revenue was up 22.4% compared to the same quarter last year. Sell-side analysts expect that Pacira Biosciences Inc will post 0.79 earnings per share for the current year.

In related news, Director Mark A. Kronenfeld acquired 1,700 shares of the stock in a transaction on Wednesday, March 6th. The shares were acquired at an average price of $38.97 per share, for a total transaction of $66,249.00. Following the transaction, the director now owns 9,277 shares in the company, valued at approximately $361,524.69. The purchase was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.90% of the company’s stock.

A number of brokerages recently commented on PCRX. Zacks Investment Research upgraded Pacira Biosciences from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a research report on Friday. BMO Capital Markets set a $46.00 target price on Pacira Biosciences and gave the company a “hold” rating in a research report on Friday, May 3rd. Piper Jaffray Companies set a $55.00 target price on Pacira Biosciences and gave the company a “buy” rating in a research report on Tuesday, April 9th. Stifel Nicolaus upgraded Pacira Biosciences from a “sell” rating to a “hold” rating and set a $45.00 target price on the stock in a research report on Thursday, May 2nd. Finally, Mizuho upgraded Pacira Biosciences from an “underperform” rating to a “neutral” rating and upped their target price for the company from $29.00 to $38.00 in a research report on Monday, May 6th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $54.40.

TRADEMARK VIOLATION WARNING: This article was published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/pacira-biosciences-inc-pcrx-holdings-lifted-by-state-board-of-administration-of-florida-retirement-system/3029192.html.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

See Also: QQQ ETF

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Biosciences Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.